Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results Aug 9, 2023
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement Jul 10, 2023
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023 Jun 5, 2023
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results May 12, 2023
Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results Mar 27, 2023
Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern Nov 14, 2022
Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting Oct 20, 2022
Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved Sep 1, 2022
Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc. Aug 31, 2022
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved Aug 15, 2022
